A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer

Alexander J. Lin, Pamela Samson, Todd DeWees, Lauren Henke, Thomas Baranski, Julie Schwarz, John Pfeifer, Perry Grigsby, Stephanie Markovina

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: Prognosis among patients with differentiated thyroid cancer is widely variable. Better understanding of biologic subtypes is necessary to stratify patients and improve outcomes. Methods: In patients diagnosed with classic histology papillary thyroid cancer treated from 1973 to 2009, BRAF V600E mutation status was determined on surgical tumor specimens by restriction fragment length polymorphism analysis. A tissue microarray (TMA) was constructed from tumor specimens in triplicate and stained by immunohistochemistry for RET, phospho-MEK, MAPK(dpERK), PPARγ, and phospho-AKT(pAKT). Stained slides were scored independently and blindly by two investigators and compared to tumor and patient characteristics and outcomes. Results: A total of 231 patients had archived formalin-fixed, paraffin-embedded tumor tissue available and were included on the TMA. Mean age at diagnosis was 44 years (range 6-82 years); proportion of patients with female sex was (72%); 2015 American Thyroid Association (ATA) risk stratification was low (26%), intermediate (32%), and high (42%). BRAF V600E mutation was found in 74% of specimens, and IHC was scored as positive for RET (61%), MAPK (dpERK) (14%), PPARγ (27%), and pAKT (39%). Positive RET staining was associated with a lower risk of recurrence (HR = 0.46, 95% CI 0.22-0.96). No other molecular biomarkers were independent predictors of recurrence on univariable analysis. On RPA, patients with RET-negative and either MAPK(dpERK)-positive or pAKT-positive tumors were identified to have a high risk of recurrence (HR = 5.4, 95%CI 2.5-11.7). This profile remained associated with recurrence in a multivariable model including ATA risk stratification (HR = 2.8, 95% CI 1.3-6.0). Conclusion: Characterization of molecular pathways involved in cPTC tumorigenesis may add further risk stratification for recurrence beyond the 2015 ATA risk categories alone.

Original languageEnglish (US)
JournalCancer Medicine
DOIs
StateAccepted/In press - Jan 1 2018

Fingerprint

Histology
Recurrence
Peroxisome Proliferator-Activated Receptors
Neoplasms
Thyroid Gland
Mutation
Mitogen-Activated Protein Kinase Kinases
Papillary Thyroid cancer
Thyroid Neoplasms
Restriction Fragment Length Polymorphisms
Paraffin
Formaldehyde
Carcinogenesis
Biomarkers
Immunohistochemistry
Research Personnel
Staining and Labeling

Keywords

  • AKT
  • BRAF
  • MAPK
  • MEK
  • PPAR
  • RET
  • thyroid cancer
  • tissue array analysis

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Cancer Research

Cite this

A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer. / Lin, Alexander J.; Samson, Pamela; DeWees, Todd; Henke, Lauren; Baranski, Thomas; Schwarz, Julie; Pfeifer, John; Grigsby, Perry; Markovina, Stephanie.

In: Cancer Medicine, 01.01.2018.

Research output: Contribution to journalArticle

Lin, Alexander J. ; Samson, Pamela ; DeWees, Todd ; Henke, Lauren ; Baranski, Thomas ; Schwarz, Julie ; Pfeifer, John ; Grigsby, Perry ; Markovina, Stephanie. / A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer. In: Cancer Medicine. 2018.
@article{5f686ee2d15a441c954d5205f82417a1,
title = "A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer",
abstract = "Background: Prognosis among patients with differentiated thyroid cancer is widely variable. Better understanding of biologic subtypes is necessary to stratify patients and improve outcomes. Methods: In patients diagnosed with classic histology papillary thyroid cancer treated from 1973 to 2009, BRAF V600E mutation status was determined on surgical tumor specimens by restriction fragment length polymorphism analysis. A tissue microarray (TMA) was constructed from tumor specimens in triplicate and stained by immunohistochemistry for RET, phospho-MEK, MAPK(dpERK), PPARγ, and phospho-AKT(pAKT). Stained slides were scored independently and blindly by two investigators and compared to tumor and patient characteristics and outcomes. Results: A total of 231 patients had archived formalin-fixed, paraffin-embedded tumor tissue available and were included on the TMA. Mean age at diagnosis was 44 years (range 6-82 years); proportion of patients with female sex was (72{\%}); 2015 American Thyroid Association (ATA) risk stratification was low (26{\%}), intermediate (32{\%}), and high (42{\%}). BRAF V600E mutation was found in 74{\%} of specimens, and IHC was scored as positive for RET (61{\%}), MAPK (dpERK) (14{\%}), PPARγ (27{\%}), and pAKT (39{\%}). Positive RET staining was associated with a lower risk of recurrence (HR = 0.46, 95{\%} CI 0.22-0.96). No other molecular biomarkers were independent predictors of recurrence on univariable analysis. On RPA, patients with RET-negative and either MAPK(dpERK)-positive or pAKT-positive tumors were identified to have a high risk of recurrence (HR = 5.4, 95{\%}CI 2.5-11.7). This profile remained associated with recurrence in a multivariable model including ATA risk stratification (HR = 2.8, 95{\%} CI 1.3-6.0). Conclusion: Characterization of molecular pathways involved in cPTC tumorigenesis may add further risk stratification for recurrence beyond the 2015 ATA risk categories alone.",
keywords = "AKT, BRAF, MAPK, MEK, PPAR, RET, thyroid cancer, tissue array analysis",
author = "Lin, {Alexander J.} and Pamela Samson and Todd DeWees and Lauren Henke and Thomas Baranski and Julie Schwarz and John Pfeifer and Perry Grigsby and Stephanie Markovina",
year = "2018",
month = "1",
day = "1",
doi = "10.1002/cam4.1857",
language = "English (US)",
journal = "Cancer Medicine",
issn = "2045-7634",
publisher = "John Wiley and Sons Ltd",

}

TY - JOUR

T1 - A molecular approach combined with American Thyroid Association classification better stratifies recurrence risk of classic histology papillary thyroid cancer

AU - Lin, Alexander J.

AU - Samson, Pamela

AU - DeWees, Todd

AU - Henke, Lauren

AU - Baranski, Thomas

AU - Schwarz, Julie

AU - Pfeifer, John

AU - Grigsby, Perry

AU - Markovina, Stephanie

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: Prognosis among patients with differentiated thyroid cancer is widely variable. Better understanding of biologic subtypes is necessary to stratify patients and improve outcomes. Methods: In patients diagnosed with classic histology papillary thyroid cancer treated from 1973 to 2009, BRAF V600E mutation status was determined on surgical tumor specimens by restriction fragment length polymorphism analysis. A tissue microarray (TMA) was constructed from tumor specimens in triplicate and stained by immunohistochemistry for RET, phospho-MEK, MAPK(dpERK), PPARγ, and phospho-AKT(pAKT). Stained slides were scored independently and blindly by two investigators and compared to tumor and patient characteristics and outcomes. Results: A total of 231 patients had archived formalin-fixed, paraffin-embedded tumor tissue available and were included on the TMA. Mean age at diagnosis was 44 years (range 6-82 years); proportion of patients with female sex was (72%); 2015 American Thyroid Association (ATA) risk stratification was low (26%), intermediate (32%), and high (42%). BRAF V600E mutation was found in 74% of specimens, and IHC was scored as positive for RET (61%), MAPK (dpERK) (14%), PPARγ (27%), and pAKT (39%). Positive RET staining was associated with a lower risk of recurrence (HR = 0.46, 95% CI 0.22-0.96). No other molecular biomarkers were independent predictors of recurrence on univariable analysis. On RPA, patients with RET-negative and either MAPK(dpERK)-positive or pAKT-positive tumors were identified to have a high risk of recurrence (HR = 5.4, 95%CI 2.5-11.7). This profile remained associated with recurrence in a multivariable model including ATA risk stratification (HR = 2.8, 95% CI 1.3-6.0). Conclusion: Characterization of molecular pathways involved in cPTC tumorigenesis may add further risk stratification for recurrence beyond the 2015 ATA risk categories alone.

AB - Background: Prognosis among patients with differentiated thyroid cancer is widely variable. Better understanding of biologic subtypes is necessary to stratify patients and improve outcomes. Methods: In patients diagnosed with classic histology papillary thyroid cancer treated from 1973 to 2009, BRAF V600E mutation status was determined on surgical tumor specimens by restriction fragment length polymorphism analysis. A tissue microarray (TMA) was constructed from tumor specimens in triplicate and stained by immunohistochemistry for RET, phospho-MEK, MAPK(dpERK), PPARγ, and phospho-AKT(pAKT). Stained slides were scored independently and blindly by two investigators and compared to tumor and patient characteristics and outcomes. Results: A total of 231 patients had archived formalin-fixed, paraffin-embedded tumor tissue available and were included on the TMA. Mean age at diagnosis was 44 years (range 6-82 years); proportion of patients with female sex was (72%); 2015 American Thyroid Association (ATA) risk stratification was low (26%), intermediate (32%), and high (42%). BRAF V600E mutation was found in 74% of specimens, and IHC was scored as positive for RET (61%), MAPK (dpERK) (14%), PPARγ (27%), and pAKT (39%). Positive RET staining was associated with a lower risk of recurrence (HR = 0.46, 95% CI 0.22-0.96). No other molecular biomarkers were independent predictors of recurrence on univariable analysis. On RPA, patients with RET-negative and either MAPK(dpERK)-positive or pAKT-positive tumors were identified to have a high risk of recurrence (HR = 5.4, 95%CI 2.5-11.7). This profile remained associated with recurrence in a multivariable model including ATA risk stratification (HR = 2.8, 95% CI 1.3-6.0). Conclusion: Characterization of molecular pathways involved in cPTC tumorigenesis may add further risk stratification for recurrence beyond the 2015 ATA risk categories alone.

KW - AKT

KW - BRAF

KW - MAPK

KW - MEK

KW - PPAR

KW - RET

KW - thyroid cancer

KW - tissue array analysis

UR - http://www.scopus.com/inward/record.url?scp=85058406868&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058406868&partnerID=8YFLogxK

U2 - 10.1002/cam4.1857

DO - 10.1002/cam4.1857

M3 - Article

JO - Cancer Medicine

JF - Cancer Medicine

SN - 2045-7634

ER -